Related Experiment Videos
Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt)
Scandinavian Journal of Urology and Nephrology. Supplementum
|January 1, 1980
Summary
Intermittent oral Estracyt treatment shows comparable efficacy to continuous therapy for prostate cancer. This approach offers reduced side effects and lower costs for patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Prostate carcinoma is a significant health concern.
- Estracyt (estradiol and nitrogen mustard) is used in prostate cancer treatment.
Purpose of the Study:
- To compare continuous versus intermittent oral Estracyt therapy for prostate carcinoma.
- To evaluate the efficacy, side effects, and cost-effectiveness of different Estracyt dosing schedules.
Main Methods:
- Prospective, randomized study design.
- Inclusion of patients diagnosed with prostatic carcinoma.
- Administration of oral Estracyt in both continuous and intermittent regimens.
Main Results:
- Intermittent Estracyt therapy demonstrated comparable therapeutic effects to continuous therapy.
- Lower incidence of side effects observed with the intermittent treatment schedule.
- Reduced treatment costs associated with the intermittent Estracyt regimen.
Conclusions:
- Intermittent oral Estracyt is a viable and potentially advantageous treatment option for prostate cancer.
- This dosing strategy may improve patient tolerance and reduce healthcare expenses.